Sponsoring Cannabis Research

 NOT LEGAL ADVICE 

For decades, cannabis research in the U.S. was stifled by Schedule I restrictions, requiring high-security vaults, mountains of paperwork, and extremely limited supply chains. With Executive Order 14370, the landscape has shifted. Marijuana is moving to Schedule III, and the rules of the game have officially changed.

In this episode of KLF Deep Dive, attorney-pharmacist Darshan Kulkarni breaks down the practical impact of this reclassification for clinical trial sponsors. We move beyond the headlines to discuss the "pharmacy-style" compliance now required and the hidden pitfalls of using non-pharmacist staff at trial sites.

Key Topics Covered:

• The Security Shift: Why you can ditch the steel vaults, but why your new "pharmacy" status brings a different set of DEA headaches.
• Supply Chain Normalization: Moving away from the "one-plant" monopoly toward a traditional pharma infrastructure.
• The Real-World Evidence (RWE) Invitation: How the FDA is encouraging the use of patient records and "real-world stories" to prove efficacy.
• The Compliance Trap: Why vetting your trial sites’ staffing—specifically the use of CRNAs vs. Pharmacists—is now a top-tier regulatory risk.
• Targeting Federal Grants: Why studies focusing on veterans and the elderly are currently "first in line" for federal support.

The Bottom Line: The federal government has moved from stopping research to starting it. But as a sponsor, your site list just got bigger—and so did your responsibility to ensure they aren't just pretending to be compliant.

Support the show: www.kulkarnilawfirm.com

Transcript

Speaker: Darshan Kulkarni

If you're interested in cannabis research, this podcast is for you. Researching cannabis was always complicated, and the Schedule 1 rules made it almost impossible. You needed high-security vaults and mountains of paperwork.

In December 2025, Executive Order 14370 proposed moving marijuana to Schedule 3, and the rules have effectively changed. There's a "reset" in research rules for cannabis. Now, let’s start at the beginning: what does Schedule 3 actually mean, and what is the impact on your daily operations?

Understanding Schedule 3

Schedule 3 is a category for drugs that have a medical use but also a potential for abuse—though it's technically less than what Schedule 1 or Schedule 2 offer. Think of your Percocets or your LSD; those would be considered your Schedule 1s or Schedule 2s, and that’s all changing as well.

Unlike Schedule 1 drugs, which are considered dangerous and have no accepted medical purpose, Schedule 3 substances can be legally prescribed by doctors. In the context of sites and companies, this is a big deal. It removes the strictest security rules, like needing massive steel vaults. Plus, it makes it cheaper and quicker to run clinical trials, and it moves products along the supply chain.

The Practical Impact

Now, I want to caution you: I've spoken to sites who do controlled substance research and they don't use pharmacists. They use CRNAs, or they use medical assistants who are "quote-unquote" pharmacists. They think it's okay. I expect that State Boards of Pharmacy would not be amused.

So, what is the practical impact?

• Security is Simpler: Under the old rules, you needed DEA-approved vaults that cost a fortune. Under Schedule 3, these requirements are much lower. But you are effectively operating like a pharmacy, and that can come with its own rules. This does mean smaller clinics and local hospitals can finally become trial sites for you. Your site list, therefore, just got a lot bigger.
  • Caution: These sites are going to pretend to be compliant. You need to know what those rules are; otherwise, your research itself can come into trouble.
• Better Supply Chain: In the past, if you were doing cannabis research, you could only get those research plants from one or two places. Now, the government is building out a research infrastructure. This will look like more "normal" pharma; you’ll have more choices and better quality control.
• Real-World Evidence: The FDA wants real-world evidence, and this is actually within the Order. The government knows that people already use medical marijuana; they want you to use that data. They don’t just want perfect lab tests anymore—you can use real-world stories and patient records to prove that your product works.

Next Steps for Sponsors

If you are a clinical trial sponsor in the cannabis space, here’s what you should do today:

1. Check your partners: Ask your sites if they're ready for Schedule 3. Then, find out why they think so. Would your State Board of Pharmacy agree? Do your physicians actually agree? Do they actually know what they're signing up for?
2. Look at the data: Consider real-world evidence. With six million people already using medical marijuana, the proof is likely out there. The FDA is literally inviting you to use that evidence.
3. Target Specific Demographics: This new order specifically mentions helping older people and veterans with pain. If your study focuses on these groups, you might be first in line for new federal grants and faster approvals.

Conclusion

The federal government is trying to enable research into cannabis. I'm not convinced that people actually want more research; they simply want more access. So, I'm not sure this is the problem they were going to solve. Having said that, the Schedule 1 barrier is adjusted. The government is moving away from stopping research to starting research.

I’m Darshan Kulkarni, and this has been a KLF deep dive into the Sponsor's Guide on Cannabis Research.